Volume 71, Issue 3
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645


Ribavirin was evaluated as a potential treatment of yellow fever (YF) in a hamster model of the disease. Ribavirin treatment during the first five days after YF virus infection improved survival, reduced tissue damage in target organs (liver and spleen), prevented hepatocellular steatosis, and normalized alanine aminotransferase levels. The results of this study suggest that ribavirin may be effective in the early treatment of YF, and that its mechanism of action in reducing liver pathology in YF virus infection may be similar to that observed with ribavirin in the treatment of chronic hepatitis C virus infection.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. McCormick JB, King IJ, Webb PA, Scribner CL, Craven RB, Johnson KM, Elliott LH, Belmont-Williams R, 1986. Lassa fever: effective therapy with ribavirin. New Engl J Med 314 : 20–26. [Google Scholar]
  2. Enria DA, Briggiler AM, Levis S, Vallejos D, Maiztegui JI, Canonico PG, 1987. Tolerance and antiviral effect of ribavirin in patients with Argentine hemorrhagic fever. Antiviral Res 7 : 353–359. [Google Scholar]
  3. Kilgore PE, Ksiazek TG, Rollin PE, Mills JN, Villagra MR, Montenegro MJ, Costales MA, Paredes LC, Peters CJ, 1997. Treatment of Bolivian hemorrhagic fever with intravenous ribavirin. Clin Infect Dis 24 : 718–722. [Google Scholar]
  4. Barry M, Russi M, Armstrong L, Geller D, Tesh RB, Dembry L, Gonzalez JP, Khan AS, Peters CF, 1995. Treatment of a laboratory-acquired Sabia virus infection. N Eng J Med 333 : 294–296. [Google Scholar]
  5. Huggins JW, Hsiang CM, Cosgriff TM, Guang MY, Smith JI, Wu ZO, LeDuc JW, Zheng ZM, Meegan JM, Wang QN, 1991. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J Infect Dis 164 : 1119–1127. [Google Scholar]
  6. Fisher-Hoch SP, Khan JA, Rehman S, Mirza S, Khurshid M, McCormick JB, 1995. Crimean-Congo haemorrhagic fever treated with oral ribavirin. Lancet 346 : 472–475. [Google Scholar]
  7. Mardani M, Jahromi MK, Naieni KH, Zeinali M, 2003. The efficacy of oral ribavirin in the treatment of Crimean-Congo hemorrhagic fever in Iran (CCHF). Clin Infect Dis 36 : 1613–1618. [Google Scholar]
  8. Huggins JW, 1989. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad spectrum antiviral drug. Rev Infect Dis 11 : S750–S761. [Google Scholar]
  9. Monath TP, Brinker KR, Chandler FW, Kemp GE, Cropp CB, 1981. Pathophysiologic correlations in a rhesus monkey model of yellow fever. Am J Trop Med Hyg 30 : 431–443. [Google Scholar]
  10. Neyts J, Meerbach A, McKenna P, de Clercq E, 1996. Use of yellow fever vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infections. Antiviral Res 30 : 125–132. [Google Scholar]
  11. Crance JM, Scaramozzino N, Jouan A, Garin D, 2003. Interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses. Antiviral Res 58 : 73–79. [Google Scholar]
  12. Buckwold VE, Wei J, Wenzel-Mathers M, Russell J, 2003. Synergistic in vitro interactions between alpha interferon and ribavirin against bovine viral diarrhea virus and yellow fever virus as surrogate models of hepatitis C virus replication. Antimicrob Agents Chemother 47 : 2293–2298. [Google Scholar]
  13. Tesh RB, Guzman H, Travassos da Rosa APA, Vasconcelos PFC, Dias LB, Bunnell JE, Zhang H, Xiao SY, 2001. Experimental yellow fever virus infection in the golden hamster (Mesocricetus auratus). I. Virologic, biochemical, and immunologic studies. J Infect Dis 183 : 1431–1436. [Google Scholar]
  14. Xiao SY, Zhang H, Guzman H, Tesh RB, 2001. Experimental yellow fever virus infection in the golden hamster (Mesocricetus auratus). II. Pathology. J Infect Dis 183 : 1437–1444. [Google Scholar]
  15. Reed LJ, Muench H, 1938. A simple method of estimating fifty percent end points. Am J Hyg 27 : 493–497. [Google Scholar]
  16. Clarke DH, Casals J, 1958. Techniques for hemagglutination and hemagglutination-inhibition of arthropod-borne viruses. Am J Trop Med Hyg 7 : 561–573. [Google Scholar]
  17. Robertson SE, Hull BP, Tomori O, Beleo O, LeDuc JW, Esteves K, 1996. Yellow fever: a decade of reemergence. JAMA 276 : 1157–1162. [Google Scholar]
  18. Monath TP, 1997. Epidemiology of yellow fever: current status and speculations on future trends. Saluzzo JF, Dodet B, eds. Factors in the Emergence of Arbovirus Diseases. Paris: Elsevier, 143–165.
  19. Xiao S-Y, Guzman H, Travassos da Rosa APA, Zhu H-B, Tesh RB, 2003. Alteration of clinical outcome and histopathology of yellow fever virus infection in a hamster model by previous infection with heterologous flaviviruses. Am J Trop Med Hyg 68 : 695–703. [Google Scholar]
  20. McArthur MA, Suderman MT, Mutebi J-P, Xiao S-Y, Barrett ADT, 2003. Molecular characterization of a hamster viscerotropic strain of yellow fever virus. J Virol 77 : 1462–1468. [Google Scholar]
  21. Bodenheimer HC Jr, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB, 1997. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 26 : 473–477. [Google Scholar]
  22. Lau JYN, Tam RC, Liang TJ, Hong Z, 2002. Mechanisms of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 35 : 1002–1009. [Google Scholar]
  23. Crotty S, Cameron C, Andino R, 2002. Ribavirin’s antiviral mechanism of action: lethal mutagenesis? J Mol Med 80 : 86–95. [Google Scholar]
  24. Inouye RT, Panther LA, Hay CM, Hammer SM, 2002. Antiviral agents. Richmond DD, Whitley RJ, Hayden FG, eds. Clinical Virology. Second edition. Washington, DC: American Society for Microbiology Press, 171–242.
  25. Monath TP, Tsai TF, 2002. Flaviviruses. Richman DD, Whitley RJ, Hayden FG, eds. Clinical Virology. Second edition. Washington, DC: American Society for Microbiology Press, 1097–1151.

Data & Media loading...

  • Received : 19 Feb 2004
  • Accepted : 31 Mar 2004

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error